Diabetes: GI Dynamics' EndoBarrier goes directly to pivotal trial in U.S., skips pilot

August 23, 2012 by MassDevice staff

GI Dynamics wins conditional approval for a pivotal clinical trial of its EndoBarrier gastrointestinal lining as treatment for diabetes and obesity, using study data from outside the U.S. to skip pilot trials.

GI Dynamics logo

GI Dynamics (ASX:GID) won conditional FDA approval for a U.S. pivotal clinical trial of the EndoBarrier gastrointestinal liner in treatment of diabetes and obesity, skipping the pilot trial process.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp